Evaluation of Chromosomal Instability in Diabetic Rats Treated with Naringin

Table 2

Frequencies of micronucleated polychromatic erythrocytes (% MNPCE) and mitotic activity (% PCE) in bone marrow of nondiabetic and diabetic rats 24 hours after the last treatment with the indicated doses of naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).

Treatment groups (mg/kg)	% MNPCE (mean ± SD)	% PCE (mean ± SD)
Nondiabetic control	0.32 ± 0.08	48.4 ± 1.81
Nondiabetic + naringin (25)	0.30 ± 0.07	48.2 ± 2.16
Nondiabetic + naringin (50)	0.28 ± 0.08	49.0 ± 1.41
Diabetes	0.92 ± 0.13**	45.6 ± 3.97
Diabetes + naringin (25)	0.60 ± 0.12^a	47.0 ± 2.54
Diabetes + naringin (50)	0.44 ± 0.11^b	47.4 ± 2.40

^∗∗𝑃<0.01 versus nondiabetic control (Kruskal-Wallis test followed by Dunn’s multiple comparisons test). ^a𝑃<0.05 and ^b𝑃<0.01 versus diabetes alone (Mann-Whitney U test).